---
schema_version: "secwatch.filing_event.v1"
accession: "0001564590-21-055942"
form_type: "8-K"
ticker: "COGT"
cik: "0001622229"
company_name: "Cogent Biosciences, Inc."
filed_at: "2021-11-10T23:59:59+00:00"
generated_at: "2026-06-28T09:58:16.900558+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Cogent Biosciences Q3 net loss $19.1M; initiates SUMMIT Phase 2, cash $202.9M

## Summary
- Net loss of $19.1M in Q3 2021 vs $50.0M in Q3 2020 (prior included $46.9M asset acquisition charge).
- Cash and equivalents $202.9M; expected to fund operations into 2024.
- Initiated SUMMIT Phase 2 trial for bezuclastinib in nonadvanced systemic mastocytosis.
- APEX Phase 2 trial for AdvSM on track for preliminary data readout H1 2022.
- Appointed Dana Martin as Chief Patient Officer and Courtney Watson as VP Clinical Development.

## SEC filing metadata
- accession: 0001564590-21-055942
- form_type: 8-K
- ticker: COGT
- cik: 0001622229
- company_name: Cogent Biosciences, Inc.
- filed_at: 2021-11-10T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1622229/000156459021055942/0001564590-21-055942-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1622229/000156459021055942/cogt-8k_20211110.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001564590-21-055942
- JSON: https://secwatch.observer/filing/0001564590-21-055942.json
- Plain text: https://secwatch.observer/filing/0001564590-21-055942.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.